Science Education
>

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

PREPARAÇÃO DO INSTRUTOR
CONCEITOS
PROTOCOLO DO ALUNO
JoVE Journal
Medicina
This content is Free Access.
JoVE Journal Medicina
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

All animal experiments were approved by the Wistar Institute Animal Care and Use Committee.

1. Generation and Maintenance of Transgenic Mice

  1. Breed LSL-K-rastm4Tyj 26 and Trp53tm1Brn 27 (obtained from NCI mouse models of human cancer consortium on a mixed background) to a full C57BL/6 background 28 by backcrossing at least 10 generations with C57BL/6 mice. To track tumor metastasis, breed B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J (LSL-EYFP, obtained from The Jackson Laboratory on a full C57BL/6 background) with double transgenic LSL-K-rasG12D/+ p53loxP/loxP mice.
    Note: Transgenic LSL-K-rasG12D/+ p53loxP/loxP mice have loxP sites flanking a transcriptionally silenced allele of oncogenic K-ras and the endogenous p53 locus, so that upon Cre-mediated excision, overexpression of an oncogenic K-ras mutant and ablation of p53 is achieved.
    Note: The LSL-EYFP mouse contains a stop codon flanking a gene for enhanced yellow fluorescent protein (YFP) that upon Cre-mediated excision results in the expression of YFP in the tissues where the YFP stop cassette is excised.
    1. Breed transgenic mice to obtain LSL-K-rasG12D/+ p53loxP/loxP mice or LSL-K-rasG12D/+ p53loxP/loxP LSL-EYFP mice for intraductal injections.
      Note: Mice are bred as homozygous for p53loxP/loxP and heterozygous for LSL-K-rasG12D/+ because mice with a homozygous deletion of K-ras die in utero. Use naïve virgin females at least six-weeks old for intraductal injections.
      Note: The primers for genotyping homozygous floxed p53 allele are p53T010-fwd (5'-AAGGGGTATGAGGGACAAGG-3') and p53-T011-rev (5'-GAAGACAGAAAAGGGGAGGG-3'). They produce a wild type allele at 391 bp and the p53 floxed allele at 461 bp29,30.
      Note: The primers to detect the mutant form of K-ras are oIMR8273 (5'-CGCAGACTGTAGAGCAGCG-3') and oIMR8274 (5'-CCATGGCTTGAGTAAGTCTGC-3'). They produce the mutant band detected at 600bp.
      Note: For the YFP reporter triple transgenic mice, the primers to detect the ROSA cassette (5'-AAGACCGCGAAGAGTTTGTC-3'), the wild type allele (5'-GGAGCGGGAGAAATGGATATG-3'), and a shared allele (5'-AAAGTCGCTCTGAGTTGTTAT-3') result in the amplification of bands at 320 bp for floxed allele and 600 bp for the wild type allele.

2. Surgical Preparation

  1. Clean surgical materials with 75% EtOH and autoclave them before and after all injections.
  2. Perform surgery on a clean uncluttered laboratory bench in a sanitized room within an animal facility. Wipe down all surfaces including the stage and dials of the surgical microscope with a broad-spectrum disinfectant solution followed by 75% EtOH.
  3. Weigh and anesthetize mice by intraperitoneal injection of a mix of ketamine (80-100 mg/kg) and xylazine (8-10 mg/kg) in sterile saline.
  4. Gently place mice back into their cages undisturbed for 5 min while they go under anesthesia. During this time generate virus precipitates (see Protocol 3).
  5. Verify lack of response to pain by toe pinching. Gently cover the eyes of anesthetized mice with veterinary ointment to prevent excessive corneal drying.
  6. To prevent hypothermia, place anesthetized mice onto a heating pad set to low heat during the surgical procedure and until they begin to recover.
  7. For the management of pain, administer mice meloxicam subcutaneously at 1 mg/kg before the surgery and 24 hr after.

3. Generation of Virus Precipitates

CAUTION: Adenovirus vectors, although they have been modified and are unable to replicate, pose the risk of infection. Handle adenovirus with caution. All personnel should be appropriately trained according to the institution's guidelines for handling BSL2 agents After intraductal injection, dispose of adenovirus in accordance with BSL2 guidelines.

  1. Store adenovirus concentrated virus stocks at -80 °C frozen in aliquots of 4 x 108 pfu each, sufficient for injecting 16 animals with 3 μl of 2.5 x 107 pfu of adenovirus particles.
  2. Store adenovirus aliquots on dry ice until approximately 15-20 min before beginning the injections.
    Note: Avoid repeated freeze thaw cycles, as virus titer drops significantly between each cycle.
    Note: Adenovirus precipitates are formed by modifying a protocol described previously 31.
  3. Reconstitute 504 mg of MEM powder with 50 ml of sterile molecular grade water, supplement with 244 mg of sodium bicarbonate and filter in sterile conditions and store at 4 °C.
    1. Prepare the calcium chloride solution by adding 1.5 g of calcium chloride to 50 ml of molecular grade water and filter in sterile conditions and store at 4 °C.
    2. Mix aliquots containing 4 x 108 pfu adenovirus-Cre with sufficient 3% sucrose in sterile water for a final volume of 10 μl. Add 34 µl of MEM to the virus and gently mix. Then add 4 μl of the CaCl2 solution, gently mix, and incubate at room temperature for 15-20 min.
    3. Store adenovirus on dry ice until ready to form precipitates. Avoid thawing of the adenovirus and storing on ice or room temperature for extended times, unless precipitates are formed.
      Note: It is also possible to mix the sucrose, MEM and CaCl2 prior to the surgeries if it is not possible to thaw the adenovirus aliquot and begin making precipitates immediately after removal from -80 °C. This aliquot of sucrose, MEM, and calcium can be saved on dry ice until ready to add the adenovirus.
      Note: Virus particles are stable for approximately 1 hr.
    4. Prior to each injection, gently flick the tube to make sure virus particles are mixed. Draw up 3 μl (2.5 x 107 pfu) of virus particles into the 10 μl syringe and prepare the mouse for the intraductal injection.

4. Intraductal Injection of Virus Particles

  1. Gently place the mouse on its back onto the illuminated stage of a clean dissection microscope. Illuminate the abdominal side with an extra light source and locate the left 4th or right 9th inguinal mammary gland by the small white patches of fur (visible on C57BL/6 females) surrounding each nipple.
  2. Rub the nipple gently with a sterile ethanol soaked cotton tipped applicator to clear hair away from the nipple and to sterilize the injection site. If they are difficult to locate, gently apply a thick layer of a depilatory cream or use shears to expose the nipples.
  3. Remove the keratin plug, a layer of dense dead skin cells, which is covering the nipple. Once the nipple is exposed, the keratin plug should be easily visible under the dissection microscope.
  4. Secure the nipple with fine surgical forceps and pull up with light force to remove the keratin plug.
  5. Stabilize the nipple between the forceps.
  6. Gently insert the needle between the forceps, cannulating the duct canal at 90°. Enter the nipple slightly past the bevel of the needle (not more than 2 mm) to prevent penetration through the mammary tissue and into the serous membranes of the ventral body cavity.
    1. Do not insert the needle too deep. To ensure proper depth of injection, gently pull the needle up after inserting it into the lumen of the duct, drawing the nipple up along the edges of the needle as it is pulled up.
      Note: Visualization of the injection is difficult; therefore practice for this step is recommended using trypan blue.
  7. When the needle is appropriately placed into the mammary duct, release the 3 µl of virus precipitates (2.5 x 107 pfu of adenovirus-Cre) by gently plunging the syringe with the thumb of the hand holding the syringe. The nipple should slightly inflate as the liquid is added.

5. Recovery of Mice

  1. Place the mouse back onto the heating pad after the injection until it begins to recover from the anesthesia.
  2. Once the mouse is recovered, place it back into a clean cage and monitor for full recovery and movement.
  3. 24 hr after the intraductal injection, subcutaneously administer meloxicam at 1 mg/kg.

6. Monitoring Tumor Progression

  1. Palpate the injected mammary gland at day 30 for enlargement and swelling.
    1. Monitor tumor progression every 5-7 days once a swollen and enlarged mammary gland is observed.
  2. Measure tumor volumes every 3-4 days for tumor growth kinetics once palpable tumors appear (approximately 50-60 days post adenoviral injection).
  3. Euthanize mice when tumor volumes exceed 10% of the body weight of the mice.

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Learning Objectives

Successful targeting of the mammary ductal tree can be visualized by preparing whole mounts of the mammary gland as previously described32 after injection of trypan blue (to verify proper injection technique (Figure 1A) or an adenovirus expressing mCherry (to verify proper viral preparation and infection of ductal epithelial cells, Figure 1B).

Figure 1
Figure 1. Intraductal targeting of mammary glands by injection with trypan blue or adenovirus-mCherry. A) A whole mount, as previously reported32, of the mammary gland after injection of mammary gland #4 with trypan blue was prepared 3 hr post injection to visualize/confirm targeting of the entire ductal tree. Images are 4X magnification. B) Infection of the ductal epithelium with adenovirus by injecting 2.5 x 107 pfu of adenovirus expressing mCherry. Mice were injected intraductally, and 4 days post-injection, a whole mount of the mammary gland was prepared to confirm viral infection of the ductal tree. Image is 4X magnification. MG is mammary gland, LD is the lactiferous, or main duct, and TD is the terminal duct. Click here to view larger image.

When tumors are induced in p53loxP/loxP LSL-K-rasG12D/+ transgenic mice, tumors will not be apparent until around day 40 when the mammary glands will become enlarged and swollen. It is necessary to begin palpations when this is observed, monitoring tumor growth every 5-7 days. In our hands, hardening of the mammary gland always precedes the onset of tumor development. Tumors will progress slowly for an additional 2 weeks. Beginning around day 56, tumors will begin to grow exponentially (Figure 2B). At this point, it is critical to measure tumor volumes every 3 days if kinetic studies are desired because there will be slight mouse to mouse variability in tumor progression, which is normal (Figures 2A and 3A). Large abdominal masses will be apparent by day 80 (Figure 2A, 2B, and 3A), after which mice should be euthanized if tumors exceed more than 10% of their body weight. cDNA analysis of three clones from a tumor-bearing mouse revealed expression of mesothelin, cytokeratin-8, Her2/neu, and estrogen receptor-α (Figure 2C).

Figure 2
Figure 2. Tumor development in p53loxP/loxP LSL-K-rasG12D/+ mice injected intraductally with adenovirus-Cre. A) Two examples of tumors 80 days after injection with adenovirus expressing Cre. Mice were given 2.5 x 107 PFU of adenovirus expressing Cre and 80 days post tumor-initiation, large palpable masses can be visualized protruding from the abdominal side of the animal. B) Typical tumor kinetics and palpation schedule for tumors induced in p53loxP/loxP LSL-K-rasG12D/+ mice. C) Characterization of three tumor cell clones derived from the same homogenized tumor of a p53loxP/loxP LSL-K-rasG12D/+ mouse. RNA was extracted and cDNA synthesized for RT-PCR analysis using primers specific to β-actin, mesothelin, cytokeratin-8, Her2/neu, progesterone receptor, estrogen receptor-α, and estrogen receptor-β. Click here to view larger image.

Similar to the cellular microenvironment in human breast cancer, we have observed infiltration of αβ and γδ T cells as well as myeloid derived suppressor cells and macrophages into the tumors (Figure 4). Vasculature draining to the axillary lymph node will begin to engorge before tumors have grown to encompass the entire mammary tissue where the injection was performed (Figure 3A). Lymphovascular invasion and metastasis of tumor cells can be tracked by crossing LSL-K-rasG12D/+ p53loxP/loxP mice with LSL-EYFP mice. After Cre-mediated excision, tumor cells expressing YFP (both high and low) are detected in the tumor and can be traced metastasizing to the draining axillary lymph node (Figure 3B). Metastasis to the distal axillary lymph node was confirmed by successfully culturing a tumor cell line from this site in a tumor-bearing LSL-K-rasG12D/+ p53loxP/loxP mouse (data not shown).

Figure 3
Figure 3. Formation of tumors and latent metastasis to the axillary lymph node. A) Example of three advanced breast tumors with different rates of tumor progression. A solid mass, indicated by the arrowhead, forms and eventually grows to the size of the entire abdominal mammary tissue. The tumor stays confined to the mammary tissue and is not observed to invade or attach to the muscle covering the peritoneal cavity. There is evident engorgement of the superficial epigastric vein between the inguinal and axillary lymph nodes, denoted by white arrowheads. After 7-8 weeks, the axillary lymph node begins to become enlarged due to lymphovascular invasion of the tumor cells, indicated by arrow. B) Metastasis of YFP positive tumor cells can be visualized in the axillary lymph node by flow cytometry. LSL-K-rasG12D/+ p53loxP/loxP LSL-EYFP mice were used to induce tumors and activation of YFP by intraductal delivery of adenovirus-Cre. To verify lymphovascular invasion of tumor cells into the axillary lymph node, 80 days post adenoviral injection, the indicated lymph nodes and organs were harvested and stained for lymphocyte markers and examined for YFP expression. CL represents contralateral nontumor draining lymph node. Results represent gating on CD45 negative tumor cells, indicating the tumor cells are invading the distal axillary lymph node. Numbers represent percent YFP positive cells from total population. Click here to view larger image.

Figure 4
Figure 4. Immune infiltrates in mouse transgenic breast tumors. Mouse breast tumors were homogenized and stained for CD45, CD3, γδTCR, CD11b and GR1. Numbers represent percent of positive leukocytes in entire tumor (63.5), total CD3+ (46.7), total CD3 negative (40.1), total CD3+ γδ+ (γδ T cells, 13), CD3+ γδnegative (24), total GR1 high CD11b (MDSC, 28.6) and total CD11b GR1 low (macrophages, 18.5). Click here to view larger image.

Due to the anatomy of the mouse and technique of intraductal injections, we find targeting of mammary glands 4 and 9 (Figure 5) yields the most consistent results and reliable injections. However, any gland can be targeted depending upon the preference of the technician performing the surgery.

Figure 5
Figure 5. Numbering of mammary ducts. Mammary ducts 4 and 9 are highlighted in red on the diagram and indicated with arrows on the mouse. In our hands, we found that injections were easiest to perform on these mammary ducts, however all other mammary tissues that we targeted developed tumors with similar kinetics. Click here to view larger image.

List of Materials

Trp53tm1Brn transgenic mice
Krastm4Tyj transgenic mice
Obtained from NCI mouse models of human cancer consortium Mice were backcrossed ten times to a full C57BL/6 background
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J Transgenic mice Jackson labs 006148
Primers p53loxp/loxp Integrated DNA Technologies 5'-AAGGGGTATGAGGGACAAGG-3'
5'-GAAGACAGAAAAGGGGAGGG-3'
Primers LSL-K-ras G12D/+ Integrated DNA Technologies 5'-CGCAGACTGTAGAGCAGCG-3'
5'-CCATGGCTTGAGTAAGTCTGC-3'
Primers for LSL-EYFP to detect Rosa promoter Integrated DNA Technologies 5'-AAGACCGCGAAGAGTTTGTC-3'
5'-GGAGCGGGAGAAATGGATATG-3'
5'-AAAGTCGCTCTGAGTTGTTAT-3'
Primers for detection of
Mesothelin expression
Integrated DNA Technologies 5'-TTGGGTGGATACCACGTCTG-3'
5'-CGGAGTGTAATGTTCTTCTGTC-3'
Primers for detection of
Progesterone Receptor expression
Integrated DNA Technologies 5'-GCAATGGAAGGGCAGCATAA-3'
5'-TGGCGGGACCAGTTGAATTT-3'
Primers for detection of
Cytokeratin 8 expression
Integrated DNA Technologies 5'-ATCAGCTCTTCCAGCTTTTCCC-3'
5'-GAAGCGCACCTTGTCAATGAAGG-3'
Primers for detection of
Erbb2 expression
Integrated DNA Technologies 5'-ACCTGCCCCTACAACTACCT-3'
5'-AAATGCCAGGCTCCCAAAGA-3'
Primers for detection of
Estrogen Receptor A expression
Integrated DNA Technologies 5'-ATGAAAGGCGGCATACGGAA-3'
5'-GCGGTTCAGCATCCAACAAG-3'
Primers for detection of
Estrogen Receptor B expression
Integrated DNA Technologies 5'-ACCCAATGTGCTAGTGAGCC-3'
5'-TGAGGACCTGTCCAGAACGA-3'
Primers for detection of
B-Actin expression
Integrated DNA Technologies 5'-GCCTTCCTTCTTGGGTATGG-3'
5'-CAGCTCAGTAACAGTCCGCC-3'
Adenovirus-CRE Gene Transfer Vector Core from the University of Iowa Ad5CMVCre Store aliquots of virus (4 x 108 pfu/aliquot) at -80C to avoid repeated freeze thaw cycles
Adenovirus-mCherry Gene Transfer Vector Core from the University of Iowa Ad5CMVmCherry Store aliquots of virus (4 x 108 pfu/aliquot) at -80C to avoid repeated freeze thaw cycles
Hamilton syringe Hamilton company 701RN 10ml syringe, RN series
Autoclave before and after each use. Clean with PBS and 75% ethanol.
Custom needle Hamilton company 7803-05 33 gauge 0.5 inch long RN needle, with a 12 degree bevel. Autoclave before and after each use. Clean with PBS and 75% ethanol.
Surgical forceps Dumont 52100-58 Dumostar No5 forceps. Clean with 75% ethanol after each use, followed by autoclaving
MEM powder Cellgro 50 012 PB Store at 4C in powder and reconstituted form
Sodium Bicarbonate Fisher S233 Add to MEM and filter stearilize
Calcium Chloride Sigma C4901 Minimum 96%, anhydrous

Preparação do Laboratório

Breast cancer is a heterogeneous disease involving complex cellular interactions between the developing tumor and immune system, eventually resulting in exponential tumor growth and metastasis to distal tissues and the collapse of anti-tumor immunity. Many useful animal models exist to study breast cancer, but none completely recapitulate the disease progression that occurs in humans. In order to gain a better understanding of the cellular interactions that result in the formation of latent metastasis and decreased survival, we have generated an inducible transgenic mouse model of YFP-expressing ductal carcinoma that develops after sexual maturity in immune-competent mice and is driven by consistent, endocrine-independent oncogene expression. Activation of YFP, ablation of p53, and expression of an oncogenic form of K-ras was achieved by the delivery of an adenovirus expressing Cre-recombinase into the mammary duct of sexually mature, virgin female mice. Tumors begin to appear 6 weeks after the initiation of oncogenic events. After tumors become apparent, they progress slowly for approximately two weeks before they begin to grow exponentially. After 7-8 weeks post-adenovirus injection, vasculature is observed connecting the tumor mass to distal lymph nodes, with eventual lymphovascular invasion of YFP+ tumor cells to the distal axillary lymph nodes. Infiltrating leukocyte populations are similar to those found in human breast carcinomas, including the presence of αβ and γδ T cells, macrophages and MDSCs. This unique model will facilitate the study of cellular and immunological mechanisms involved in latent metastasis and dormancy in addition to being useful for designing novel immunotherapeutic interventions to treat invasive breast cancer.

Breast cancer is a heterogeneous disease involving complex cellular interactions between the developing tumor and immune system, eventually resulting in exponential tumor growth and metastasis to distal tissues and the collapse of anti-tumor immunity. Many useful animal models exist to study breast cancer, but none completely recapitulate the disease progression that occurs in humans. In order to gain a better understanding of the cellular interactions that result in the formation of latent metastasis and decreased survival, we have generated an inducible transgenic mouse model of YFP-expressing ductal carcinoma that develops after sexual maturity in immune-competent mice and is driven by consistent, endocrine-independent oncogene expression. Activation of YFP, ablation of p53, and expression of an oncogenic form of K-ras was achieved by the delivery of an adenovirus expressing Cre-recombinase into the mammary duct of sexually mature, virgin female mice. Tumors begin to appear 6 weeks after the initiation of oncogenic events. After tumors become apparent, they progress slowly for approximately two weeks before they begin to grow exponentially. After 7-8 weeks post-adenovirus injection, vasculature is observed connecting the tumor mass to distal lymph nodes, with eventual lymphovascular invasion of YFP+ tumor cells to the distal axillary lymph nodes. Infiltrating leukocyte populations are similar to those found in human breast carcinomas, including the presence of αβ and γδ T cells, macrophages and MDSCs. This unique model will facilitate the study of cellular and immunological mechanisms involved in latent metastasis and dormancy in addition to being useful for designing novel immunotherapeutic interventions to treat invasive breast cancer.

Procedimento

Breast cancer is a heterogeneous disease involving complex cellular interactions between the developing tumor and immune system, eventually resulting in exponential tumor growth and metastasis to distal tissues and the collapse of anti-tumor immunity. Many useful animal models exist to study breast cancer, but none completely recapitulate the disease progression that occurs in humans. In order to gain a better understanding of the cellular interactions that result in the formation of latent metastasis and decreased survival, we have generated an inducible transgenic mouse model of YFP-expressing ductal carcinoma that develops after sexual maturity in immune-competent mice and is driven by consistent, endocrine-independent oncogene expression. Activation of YFP, ablation of p53, and expression of an oncogenic form of K-ras was achieved by the delivery of an adenovirus expressing Cre-recombinase into the mammary duct of sexually mature, virgin female mice. Tumors begin to appear 6 weeks after the initiation of oncogenic events. After tumors become apparent, they progress slowly for approximately two weeks before they begin to grow exponentially. After 7-8 weeks post-adenovirus injection, vasculature is observed connecting the tumor mass to distal lymph nodes, with eventual lymphovascular invasion of YFP+ tumor cells to the distal axillary lymph nodes. Infiltrating leukocyte populations are similar to those found in human breast carcinomas, including the presence of αβ and γδ T cells, macrophages and MDSCs. This unique model will facilitate the study of cellular and immunological mechanisms involved in latent metastasis and dormancy in addition to being useful for designing novel immunotherapeutic interventions to treat invasive breast cancer.

Tags